IMMUNOCORE HLDGS ADS/1 - Asset Resilience Ratio

Latest as of December 2025: 37.15%

IMMUNOCORE HLDGS ADS/1 (6YG) has an Asset Resilience Ratio of 37.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€396.44 Million

≈ $463.48 Million USD Cash + Short-term Investments

Total Assets

€1.07 Billion

≈ $1.25 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how IMMUNOCORE HLDGS ADS/1's Asset Resilience Ratio has changed over time. Check strategic asset allocation of IMMUNOCORE HLDGS ADS/1 to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down IMMUNOCORE HLDGS ADS/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 6YG company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€396.44 Million	37.15%
Total Liquid Assets	€396.44 Million	37.15%

Asset Resilience Insights

Very High Liquidity: IMMUNOCORE HLDGS ADS/1 maintains exceptional liquid asset reserves at 37.15% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

IMMUNOCORE HLDGS ADS/1 Industry Peers by Asset Resilience Ratio

Compare IMMUNOCORE HLDGS ADS/1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for IMMUNOCORE HLDGS ADS/1 (2023–2025)

The table below shows the annual Asset Resilience Ratio data for IMMUNOCORE HLDGS ADS/1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	37.15%	€396.44 Million ≈ $463.48 Million	€1.07 Billion ≈ $1.25 Billion	+1.02pp
2024-12-31	36.12%	€364.64 Million ≈ $426.31 Million	€1.01 Billion ≈ $1.18 Billion	--
2023-12-31	0.00%	€0.00 ≈ $0.00	€597.00 Million ≈ $697.96 Million	--

pp = percentage points

About IMMUNOCORE HLDGS ADS/1

F:6YG Germany Biotechnology

Market Cap

$1.47 Billion

€1.26 Billion EUR

Market Cap Rank

#7527 Global

#1041 in Germany

Share Price

€24.80

Change (1 day)

-1.59%

52-Week Range

€24.60 - €34.60

All Time High

€69.50